ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

In China, the number of patients with atopic dermatitis continues to ... and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

Biosion’s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis ... indicative of its potential ...

Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN ...

The treatment for keratosis pilaris is continuous. The condition needs to be maintained. General measures to prevent ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...

So for long term treatment of allergies ... If we're talking about, kind of the flip side of this, which is the best long-term management of atopic dermatitis, as well as those JAK inhibitors work, ...

UST, a leading digital transformation solutions company, has opened a new office and state-of-the-art Generative AI Experience Center in Cyberjaya, Selangor, Malaysia. This facility will act as a hub ...